The Way Forward for Reproductive/Developmental Toxicity Testing Comments I was somewhat surprised when I saw Mary Moxon's Guest Editorial, "Developmental and reproductive toxicity testing: a potted history", in Lab Animal Europe earlier this year. 1 Contrary to what I had read and heard repeatedly over several years, she clearly believed that laboratory animal tests are a sound basis for human risk assessment and will continue to be used "to protect our future generations".
However, since I am not a reproductive toxicologist, I decided to seek comments on the Editorial from three individuals with much greater experience in the field. All three of them accepted my invitation, and their comments follow this introduction. [2] [3] [4] I decided not to produce a lengthy response of my own. However, I do want to refer the readers of ATLA to one particularly important paper, by Bremer, Pellizer, Hoffmann, Seidle and Hartung, 5 on "The development of new concepts for assessing reproductive toxicity applicable to large scale toxicological programmes".
Bremer et al. referred to the need to incorporate the emerging technologies into toxicity testing, taking into account the need to review the traditional approaches to toxicology, not least because inter-species differences limit the value of animal data for predicting human hazards. In the case of developmental toxicity testing, there is a correlation of less that 60% between the results obtained in different laboratory animal species. As a result, the "precautionary" response in regulatory toxicology is to use more than one species. Nevertheless, that does not mean that the outcome will have any relevance to humans, and there is the serious risk of overlabelling due to an enormous number of false-positive results, whilst chemicals truly likely to have serious effects in humans will go undetected.
As Bremer et al. point out, reproductive toxicity testing in animals, in compliance with the EU REACH system for new and existing chemicals, conducted according to the current procedures, would require up to 3,200 animals per substance. Applied to thousands of chemicals, in addition to causing unnecessary suffering to animals, the economic costs would be unsupportable, and the outcome would be unlikely to contribute meaningfully to the protection of human health.
They say that new concepts need to be developed, "based on the knowledge of already existing data on reproductive toxicants, rather than requesting more testing following the traditional scheme. A major component of more science-based concepts is a careful determination of prevalence" (i.e. the proportion of chemicals within the universe of industrial chemicals which are reproductive toxicants) "with the support of high quality databases. Testing for the detection of adverse effects with low prevalences will lead to unnecessary animal testing but also to a high rate of falsepositives". For example, if the correlation between species was 60% and the prevalence of developmental toxicity to humans among 1000 chemicals was 5%, testing in the rat and rabbit according to the current regulatory guidance would result in 608 false-positive results, 42 true-positive results, 342 true-negative results and 8 false-negative results. 5 Even if this is a theoretical estimation, and whatever the real figures are, the problem remains: it would not be possible to know which of the outcomes from the rat and rabbit testing were true and which were false as far as humans were concerned! Thus, as Bremer et al. and others have pointed out (e.g. Grindon et al. 6 ), there is a need for scientifically-based, intelligent testing strategies, which make full use of the emerging alternative technologies. In addition, it is necessary to increase the confidence of decision-making bodies in the validation process for alternative methods and to insist that there is an urgent need for a re-evaluation of the relevance and reliability of the currentlyaccepted in vivo test guidelines. 7 
Michael Balls

